Nektar Therapeutics Revenue, Profits - NKTR Quarterly Income Statement

Add to My Stocks
$58.44 $1.75 (3.09%) NKTR stock closing price Sep 20, 2018 (Closing)

Financial analysis of Nektar Therapeutics involves more than just checking the Nektar Therapeutics stock price, by looking at the financial statements of the company in detail. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $1.09B for 2018 Q2 impacts the NKTR stock. Investors typically check year over year or quarter over quarter revenue growth. Revenue for year 2018 Q2 is $1.09B and has increased from $38.02M quarter on quarter as is evident when you compare the latest figures in the latest Nektar Therapeutics profit and loss statement with those of the prior corresponding period. Also see Nektar Therapeutics assets and Nektar Therapeutics free cash flow for a complete valuation of NKTR stock.

View and download details of revenue and profits for Nektar Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Nektar Therapeutics Revenues or Net Sales
1.09B38.02M95.47M152.93M34.59M24.73M37.45M36.34M32.77M58.88M
Cost Of Goods Sold (COGS)5.52M6.64M9.76M5.67M8.98M6.13M6.61M7.03M7.7M8.87M
Nektar Therapeutics Gross Profit
1.08B31.37M85.72M147.25M25.6M18.59M30.85M29.3M25.06M50.01M
Research & Development Expense88.33M99.42M81.44M65.71M60.26M61.05M50.24M51.95M52.35M49.26M
Selling General & Admin Expense20.26M18.68M28.33M12.05M15.99M11.97M12.77M10.25M11.03M10.22M
Income Before Depreciation Depletion Amortization973.6M-86.73M-24.04M69.48M-50.65M-54.43M-32.15M-32.9M-38.32M-9.48M
Depreciation Depletion Amortization----------
Non Operating Income12.11M1.57M1.38M1.59M------
Interest Expense10.36M10.35M10.97M10.01M10.02M9.95M10.35M10.51M10.6M10.72M
Nektar Therapeutics Pretax Income
975.35M-95.52M-33.64M61.07M-59.77M-63.73M-41.76M-43.08M-48.47M-19.33M
Provision for Income Taxes3.89M---------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations971.46M-95.79M-33.83M60.87M-59.87M-63.87M-42.2M-43.22M-48.6M-19.5M
Extraordinary Items & Discontinued Operations----------
Nektar Therapeutics Profit/ Loss (Net Income)
971.46M-95.79M-33.83M60.87M-59.87M-63.87M-42.2M-43.22M-48.6M-19.5M
Average Shares used to compute Diluted EPS182.29M160.88M158.32M162.64M155.35M153.67M149.07M137.09M136.35M135.79M
Average Shares used to compute Basic EPS171.38M160.88M158.32M156.41M155.35M153.67M149.07M137.09M136.35M135.79M
Income Before Nonrecurring Items971.46M-95.79M-23.44M60.87M-59.87M-63.87M-42.2M-43.22M-48.6M-19.5M
Income from Nonrecurring Items---10.39M-------
Nektar Therapeutics Earnings Per Share Basic Net
5.67-0.60-0.210.39-0.39-0.42-0.28-0.32-0.36-0.14
Nektar Therapeutics Earnings Per Share Diluted Net
5.33-0.60-0.210.37-0.39-0.42-0.28-0.32-0.36-0.14
EPS Diluted Before Nonrecurring Items5.33-0.60-0.140.37-0.39-0.42-0.28-0.32-0.36-0.14
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Nektar Therapeutics stock analysis. It helps to look at the following income statement items:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $1.09B for this quarter of 2018 Q2. Our Nektar Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like Nektar Therapeutics try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the NKTR income statement, one can check the Nektar Therapeutics historical stock prices to check how the price has moved with time.

Nektar Therapeutics Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
11.95
PS Ratio (price sales ratio)
7.29
Operating Margin
89.5
Net Profit Margin
89.3
Dividend Yield
0%